AC
IMVT icon

Armistice Capital’s Immunovant IMVT Stock Holding History

Armistice Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.2M Buy
1,900,000
+1,150,000
+153% +$29.8M 0.84% 18
2025
Q4 		$19.1M Buy
+750,000
New +$16.7M 0.23% 73
2025
Q2 		– Sell
-900,000
Closed -$15.4M – 236
2025
Q1 		$15.4M Sell
900,000
-450,000
-33% -$9.41M 0.23% 78
2024
Q4 		$33.4M Buy
1,350,000
+770,000
+133% +$21.8M 0.46% 41
2024
Q3 		$16.5M Buy
+580,000
New +$17.1M 0.26% 78

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Armistice Capital's IMVT Position: Q1 2026 in Review

Armistice Capital reduced its Immunovant (IMVT) stake by 38% in Q1 2026, selling an estimated $56.5M and leaving 3,564,916 shares worth $88.6M. The position accounts for 1.57% of the portfolio, ranked #11.

Armistice Capital first reported a position in IMVT in Q3 2023 and has held it in 11 quarters since. The position peaked at $146M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Armistice Capital held 3,564,916 shares of Immunovant worth $88.6M as of Q1 2026.
  • Armistice Capital sold 2,182,239 Immunovant shares in Q1 2026, an estimated $56.5M.
  • Immunovant made up 1.57% of Armistice Capital's portfolio in Q1 2026, its #11 holding.
  • Armistice Capital first reported a position in Immunovant in Q3 2023 and has held it in 11 quarters since.
  • Armistice Capital's Immunovant position peaked at $146M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.